A Phase 2 interventional study of ASP2151 and valacyclovir in Herpes Genitalis, sponsored by Astellas Pharma Inc. Completed at 25 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-07.
Sponsored by Astellas Pharma Inc · Phase 2, Interventional, and Treatment
A study of ASP2151 in subjects with recurrent outbreaks of genital herpes.
305 studies on the registry are indexed under Herpes Simplex; 31 are open to participants now.
This study's enrollment of 695 is above the median of 101 across 227 interventional studies indexed under Herpes Simplex.
Browse Herpes Simplex studies →Astellas Pharma Inc is the lead sponsor of 512 studies on the registry; 4 are open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 19 (70%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Oral administration of active comparator
Drug: valacyclovir
Oral administration of placebo
Drug: Placebo
Dosing regimen 1
Drug: ASP2151
Dosing regimen 2
Drug: ASP2151
Dosing regimen 3
Drug: ASP2151
Dosing regimen 4
Drug: ASP2151
Oral administration.
Oral administration of active comparator.
Oral administration of placebo.
To compare the efficacy and safety of ASP2151 with valacyclovir and placebo in the acute treatment of recurrent genital Herpes Simplex Virus Infection
Time frame: 17 days
Pharmacokinetics in study patients
Time frame: 4 days
Plan to share: Undecided
This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Astellas Pharma Inc